Liver clues: a new way to stage heart amyloidosis?

This study looks at whether liver function and blood clotting tests can help doctors better understand and monitor cardiac transthyretin amyloidosis (ATTR-CA), a condition where abnormal protein builds up in the heart. Researchers will compare these tests in people with ATTR-CA against those with another type of heart muscle disease. They will also check if these markers change after 6 and 12 months of treatment with tafamidis, a medication used for this condition. The goal is to find new tools for staging the disease and tracking its progression.